HOME >> BIOLOGY >> NEWS
Dartmouth professor makes case for ethically universal stem cell lines

HANOVER, NH -- Human embryonic stem cells (hESC), those very young cells that are a biological blank slate, have the potential to become more specialized, contributing to the workings of a wide variety of organs and tissues. Their potential to treat diseases such as Parkinsons is slow to be realized because of the ongoing ethical debate over harvesting hESCs, a process called deriving hESC lines. Additionally, its a politically charged issue in the U.S. because it involves federal funding for research.

A recently published paper by Dartmouth Professor Ronald M. Green examines the moral questions and the scientific feasibility of deriving hESC lines in ways that avoid destroying living human embryos. The paper, published in the June 2007 issue of Nature Reviews Genetics, considers six current approaches: altered nuclear transfer, parthenogenesis, single-blastomere biopsy, somatic-cell dedifferentiation, the use of dead embryos, and the use of abnormal embryos. Greens goal, as stated in the paper, is to greatly accelerate hESC research that is closer to being universally acceptable.

I think we can pursue hESC research and also respect the sensitivities of our fellow citizens. Its not impossible to do both, says Green, the Eunice and Julian Cohen Professor for the Study of Ethics and Human Values, and the faculty director of the Dartmouth Ethics Institute. In addition to resolving current debates, he argues, these alternatives can make possible hESC lines that are ethically universal. These would be analogous to the universal O-type blood group: lines that could be used by anyone regardless of their ethical views on the moral status of the embryo.

Green, who is also an adjunct professor of community and family medicine at the Dartmouth Medical School, says, The six approaches differ in technique, most directly in how the blastocyst is created. The blastocyst, where hESCs are found, is the three- to five-day-old embryo that has not yet
'"/>

Contact: Sue Knapp
sue.knapp@dartmouth.edu
603-646-3661
Dartmouth College
7-Jun-2007


Page: 1 2

Related biology news :

1. Plants that produce more vitamin C may result from UCLA-Dartmouth discovery
2. Vitamin extends life in yeast, Dartmouth Medical School researchers find
3. Dartmouth researchers find that arsenic triggers unique mechanism in rare leukemia
4. Dartmouth researchers find that low doses of arsenic have broad impact on hormone activity
5. Dartmouth researchers identify a gene that enhances muscle performance
6. Dartmouth study contributes to research addressing malnutrition and iron deficiency
7. Genetic variation impacts aspirins effectiveness in preventing colon cancer, Dartmouth study finds
8. Dartmouth researchers find a neural signature of bilingualism
9. Dartmouth and GlycoFi report full humanization of therapeutic proteins from yeast
10. GlycoFi and Dartmouth report full humanization of yeast glycosylation pathway in Science
11. Dartmouth researchers find key player in immune system regulation

Post Your Comments:
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014The development of stem ... on the ability to characterize stem cell populations based ... Cross have discovered a new marker that is highly ... human umbilical cord blood, which they describe in an ... journal from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
(Date:4/17/2014)... German . ... also provide us with a continuous stream of information about ... sit still in a car the world glides by ... Seemingly without effort, our brain calculates self-motion from this "optic ... a steady gaze during our own movements. Together with biologists ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
Cached News: